Roughly a quarter of UK Pompe patients on long-term ERT are inadequate responders, the target population for avalglucosidase alfa.

Pompe disease is caused by acid alpha-glucosidase (GAA) deficiency, and the UK Pompe Consortium, an academic-clinical network spanning GSTT/King's, Manchester, Birmingham, Addenbrooke's, and Edinburgh, coordinates shared care, a national registry, and research across an estimated 200 UK patients combining infantile-onset and late-onset disease. Unlike some Gulf markets, the NHS newborn-screening programme does not currently include Pompe disease, so infantile-onset cases, roughly 12-18 a year, are diagnosed symptomatically; late-onset disease is typically diagnosed 5-10 years after first symptom, frequently misread initially as a limb-girdle myopathy.

The UK LOPD diagnostic pathway runs from unexplained proximal myopathy and elevated creatine kinase through metabolic genetics referral to a dried-blood-spot GAA enzyme assay and confirmatory gene sequencing, offered free through the NHS Genomic Medicine Service, a journey the UK Pompe Consortium estimates at 3-8 years from first symptom. Alglucosidase alfa has never been formally appraised by NICE; enzyme replacement therapy continuation is instead governed by NHS clinical commissioning policy, which requires lung-function and walk-test monitoring at baseline, 12, and 24 months, with continuation contingent on at least 10% improvement or stabilisation. Roughly 60% of patients on ERT for more than five years show continued stabilisation, but around 25%, an estimated 45-50 UK patients, show decline despite treatment and are the immediate target for avalglucosidase alfa, already NICE-recommended as TA821.

A quarter of treated patients keep declining; next-generation ERT already has NICE backing.

Five questions this report answers:

Q1 - How does the UK Pompe Consortium's network shape diagnosis across the roughly 200-patient population?

Q2 - What is the size of the inadequate-ERT-responder subset now eligible for avalglucosidase alfa (TA821)?

Q3 - What drives the 3-8 year UK diagnostic delay for late-onset Pompe disease?

Q4 - Why doesn't NHS newborn screening currently include Pompe disease, unlike some Gulf markets?

Q5 - What continuation criteria, like lung-function and walk-test results, govern ongoing NHS ERT funding?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#PompeDisease #NICE #NHS #RareDisease #EnzymeReplacementTherapy #UK

Live report page:  https://axlrx.ai/pompe-disease/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/